Melbourne-based Immuron (ASX: IMC) has announced the appointment of Mr Thomas Liquard as the company's new CEO.
Mr Liquard will commence on 31 August, joining the company from Alchemia, where he served as CEO and formerly Chief Operating Officer.
"Throughout his time with Alchemia, Mr Liquard managed a $22 million operating Budget, brought two major investors onto the register, and led all major business development and corporate development activities for the company," said Immuron in a statement.
Prior to joining Alchemia, Mr Liquard spent seven years with Pfizer based in New York, where he held various senior commercial roles.
In his last role with the company, he was Senior Director, Portfolio Development Leader Emerging Markets for its Established Products business.
"The Board are very pleased to have Mr Liquard joining our team as CEO at Immuron, and we feel he will be the right leader to elevate Immuron to its next level and drive our most recent overseas opportunities for both product development and diversified investment," said Chairman Dr Roger Aston. "Thomas will be based in New York for the first 12 months of his appointment in order to focus the Company's activities in this larger market which were recently initiated by the Board."
Dr Aston added, "The US represents a very significant opportunity and having Thomas located in New York will help us maximise the sales of Travelan and more importantly help the market recognise the high value prospects of Immuron when compared to its peer US listed Biotech companies."
Liquard said he was very excited to join Immuron.
"The company has developed a novel and broad technology platform that has the potential to yield multiple drug candidates for the treatment and prevention of hard-to-treat diseases, and therefore create substantial shareholder value," he said.
"Being based in the US over the next few months, will provide Immuron with a great opportunity to accelerate the Company's momentum by leveraging my extensive network, helping grow revenues and expanding the capital base."